Monday, August 4, 2014

America Reveals Secret Ebola Cure! Experimental Drug 'Reverses' Infection in Sick Missionaries

Posted in: , ,

An experimental drug for Ebola called ZMapp may likely have saved the lives of the 2 US aid workers, Dr. Kent Brantly and Nancy Writebol, who contracted the virus while working in Liberia.

According to reports, three vials containing the experimental drug stored at subzero temperatures were flown into Liberia last week in a last-ditch effort to save the two American missionary workers.

The drug appears to have worked, and Dr. Kent Brantly's and Nancy Writebol's conditions significantly improved after receiving the medication, sources say.

Could the drug explain why the American Government allowed the aid workers to be flown home, because they were already cured?

Also, while I'm happy for the aid workers, and glad there's a cure in sight, I want to know if this drug meant for Americans alone? There are people dying in Sierra Leone, Liberia and Guinea who could do with this drug.

Just days after taking the drug, Brantly was able to walk on his own into Emory University Hospital in Atlanta after being evacuated to the United States on Saturday, and Writebol is expected to arrive in Atlanta tomorrow.

Read part of the complete report below from CNN...

On July 22, Brantly woke up feeling feverish. Fearing the worst, Brantly immediately isolated himself. Writebol's symptoms started three days later. A rapid field blood test confirmed the infection in both of them after they had become ill with fever, vomiting and diarrhea.

It's believed both Brantly and Writebol, who worked with the aid organization Samaritan's Purse, contracted Ebola from another health care worker at their hospital in Liberia, although the official Centers for Disease Control and Prevention case investigation has yet to be released.

A representative from the National Institutes of Health contacted Samaritan's Purse in Liberia and offered the experimental treatment, known as ZMapp, for the two patients, according to the source.

The drug was developed by the biotech firm Mapp Biopharmaceutical Inc., which is based in San Diego. The patients were told that this treatment had never been tried before in a human being but had shown promise in small experiments with monkeys.

According to company documents, four monkeys infected with Ebola survived after being given the therapy within 24 hours after infection. Two of four other monkeys that started therapy within 48 hours after infection also survived. One monkey that was not treated died within five days of exposure to the virus.

Brantly and Writebol were aware of the risk of taking a new, little understood treatment and gave informed consent, according to two sources familiar with the care of the missionary workers. In the monkeys, the experimental serum had been given within 48 hours of infection. Brantly didn't receive it until he'd been sick for nine days.

The medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine. It works by preventing the virus from entering and infecting new cells.

The Ebola virus causes viral hemorrhagic fever, which refers to a group of viruses that affect multiple organ systems in the body and are often accompanied by bleeding.

Early symptoms include sudden onset of fever, weakness, muscle pain, headaches and a sore throat. They later progress to vomiting, diarrhea, impaired kidney and liver function -- and sometimes internal and external bleeding.

The ZMapp vials reached the hospital in Liberia where Brantly and Writebol were being treated Thursday morning. Doctors were instructed to allow the serum to thaw naturally without any additional heat. It was expected that it would be eight to 10 hours before the medicine could be given, according to a source familiar with the process.

Brantly asked that Writebol be given the first dose because he was younger and he thought he had a better chance of fighting it, and she agreed. However, as the first vial was still thawing, Brantly's condition took a sudden turn for the worse.

Brantly began to deteriorate and developed labored breathing. He told his doctors he thought he was dying, according to a source with firsthand knowledge of the situation.

Knowing his dose was still frozen, Brantly asked if he could have Writebol's now-thawed medication. It was brought to his room and administered through an IV. Within an hour of receiving the medication, Brantly's condition dramatically improved. He began breathing easier; the rash over his trunk faded away. One of his doctors described the events as "miraculous."

By the next morning, Brantly was able to take a shower on his own before getting on a specially designed Gulfstream air ambulance jet to be evacuated to the United States.

Writebol also received a vial of the medication. Her response was not as remarkable, according to sources familiar with the treatment. However, doctors on Sunday administered Writebol a second dose of the medication, which resulted in significant improvement.

She was stable enough to be evacuated back to the United States and is expected to arrive before noon Tuesday.


  1. Only one question? Why are we only hearing about this now, and when will it get to Africa where it is really needed?

  2. So if Oyibo does not intervene, we can't help ourselves? There is no Ebola cure or vaccine because until this recent widespread outbreak it was affecting mostly Africans and what was the response, smh. Same thing for Malaria and Polio na Oyibo man dey carry the research etc for head, day and night they are researching and funding research centers for all sorts of things. and i am sure by Gods grace they will have a breakthrough with all the years of cancer research. What I am saying is corruption would not let us be great. If we had the facilities we should be able to contain this virus. just see the measures the Americans put in place for those two citizens they flew back.

  3. This is an experimental serum that was developed in Canada (not America) at the National Microbiology Lab. It has only been used (to our knowledge) once by a German scientist when she was infected. The issue is that we dont have institutions that can do a quick assesment of risk vs. ethics. And if this experimental drug is now provided without explicit consent and without knowing side effects there will be huge outcry that Africans are being used as a guinea pig. Besides - given that experimental nature of the drug, it cannot be produced in enough quantities to deal with the current epidemic that we have now.

    1. ZMappTM is the result of a collaboration between Mapp Biopharmaceutical, Inc. and LeafBio (San Diego, CA), Defyrus Inc. (Toronto, Canada), the U.S. government and
      the Public Health Agency of Canada (PHAC).
      ZMappTM is composed of three “humanized” monoclonal antibodies manufactured in
      plants, specifically Nicotiana. It is an optimized cocktail combining the best
      components of MB-003 (Mapp) and ZMAb (Defyrus/PHAC).
      ZMappTM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans. As such, very little of the drug is currently available.
      Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA.
      Mapp and its partners are cooperating with appropriate government agencies to increase production as quickly as possible.


Click Post a Comment to share your thoughts, I'll love to hear from you. Thanks!

*Comments on old posts are moderated and may take sometime to be shown. That's just because I want to see them and respond to you if necessary.